. . . . . . . "[The ADAS-cog15 was the primary efficacy measure; function, cognition, behavior, and quality of life were assessed as secondary measures; cerebral atrophy in MRI and the levels of tau, amyloid-?, and BACE1 in cerebrospinal fluid (CSF) were exploratory endpoints.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:18:16+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .